GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » Revenue

Cannara Biotech (TSXV:LOVE) Revenue : C$73.34 Mil (TTM As of Feb. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Revenue?

Cannara Biotech's revenue for the three months ended in Feb. 2024 was C$19.68 Mil. Its revenue for the trailing twelve months (TTM) ended in Feb. 2024 was C$73.34 Mil. Cannara Biotech's Revenue per Share for the three months ended in Feb. 2024 was C$0.22. Its Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 was C$0.82.

Warning Sign:

Cannara Biotech Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Cannara Biotech was 57.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 161.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 154.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 6 years, Cannara Biotech's highest 3-Year average Revenue per Share Growth Rate was 233.20% per year. The lowest was 128.90% per year. And the median was 161.10% per year.


Cannara Biotech Revenue Historical Data

The historical data trend for Cannara Biotech's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Revenue Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Revenue
Get a 7-Day Free Trial 2.10 2.55 17.02 35.84 57.26

Cannara Biotech Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.04 15.84 18.33 19.48 19.68

Competitive Comparison of Cannara Biotech's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Revenue distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Revenue falls into.



Cannara Biotech Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$73.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannara Biotech  (TSXV:LOVE) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Cannara Biotech Revenue Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech (TSXV:LOVE) Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
Executives
Olymbec Investments Inc. 10% Security Holder
Derek Elan Stern Director

Cannara Biotech (TSXV:LOVE) Headlines

From GuruFocus

LOVESAC INVESTOR DEADLINE APPROACHING

By PRNewswire 01-04-2024